GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Net Interest Income (for Banks)

Invex Therapeutics (ASX:IXC) Net Interest Income (for Banks)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Invex Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.